A bold initiative is underway at Western University, challenging the status quo and aiming to revolutionize access to life-saving medical breakthroughs. The question at its core is simple yet profound: why shouldn't everyone, regardless of their geographical location, have equal access to these advancements from the very beginning?
For Eric Arts, a renowned virologist and Canada Research Chair, this isn't just an ethical dilemma but a pressing issue. With decades of experience in HIV research, Arts has witnessed the incredible power of biomedical discoveries, but also the painful reality of delayed access for those who need it most.
"Where you live should not determine your access to medical breakthroughs," Arts emphasizes. "In the world of HIV, this inequality is painfully evident."
Over the past three decades, antiretroviral therapy (ART) has transformed HIV from a death sentence to a manageable condition. However, the distribution of these advanced therapies has been far from equal. In sub-Saharan Africa, where the HIV burden is highest, people have waited years, even decades, for the same innovations available in wealthier nations. Many treatment programs rely on unstable international aid and government funding, putting millions of lives at risk.
Today, approximately 40 million people worldwide are living with HIV, most requiring daily medication for life. While a cure technically exists, it is not a solution that reaches everyone who needs it.
Enter IMMUNEQUITY, a groundbreaking public-private international collaboration led by Arts and a diverse team of experts. This initiative aims to reimagine the development of HIV cures, ensuring that scientific innovation, affordability, manufacturability, and equitable accessibility are treated as inseparable goals. In simpler terms, they're on a mission to find an equitable solution to the global HIV pandemic.
"The opportunity to design a potentially curative HIV therapy with manufacturability, cost, and global accessibility as top priorities from day one is incredibly exciting," says Peter Zandstra, Canada Research Chair in Stem Cell Engineering. "If we can tackle the manufacturing and distribution challenges alongside the biology, the impact could be immense, reaching millions worldwide."
The current proven cure for HIV involves hematopoietic stem cell transplantation (HSCT), an intensive and expensive procedure. Scaling such a procedure globally is financially daunting, and beyond the cost, HSCT requires advanced infrastructure that is lacking in many low- and middle-income countries. For Arts and his team, this reality highlights a critical flaw in the traditional approach to biomedical innovation: cures are often developed first, with accessibility being an afterthought.
IMMUNEQUITY aims to change this narrative. At its scientific core is the 'kick and kill' strategy, where HIV, which persists by hiding in dormant immune cells, is exposed and then targeted for elimination. Instead of relying on toxic chemotherapies, Arts, Zandstra, and their collaborators will focus on 'biologics' or precision immunotherapies, such as antibodies and virus-like particles, specifically designed to target HIV-infected cells.
"These modern medical tools are incredibly powerful, and by removing pharmaceutical profit margins for low-income countries, we can produce them at a fraction of the cost," Arts explains.
Even more importantly, the manufacturing of biologics is far more feasible in low- and middle-income countries compared to transplant-based cures or chemical-based drugs. This insight fundamentally changes the development strategy.
Through Western's Frugal Biomedical Innovations program, researchers from various disciplines will collaborate to rethink the design and development of tools for manufacturing biotherapeutics and for the diagnosis and monitoring of HIV. The goal is to ensure that the eventual cure is not only effective but also affordable and sustainable.
"New biotherapeutics must be designed with an understanding of the realities of low-resource health systems," says Maria Drangova. "They need to be developed alongside scalable manufacturing, reliable infrastructure, and quality systems to ensure they are safe, affordable, and accessible where they are needed most."
In this model, cost and deployment are given the same importance as biological efficacy. The team recognizes that each region or country has its own unique context, and they aim to work alongside people living with HIV in Canada and Uganda to ensure that legal, social, ethical, and cultural factors shape the project.
Bassem Awad, founder of the Western Intellectual Property and Innovation Legal Clinic, will design IMMUNEQUITY's intellectual property strategy and data governance framework to remove legal barriers and accelerate the development and deployment of new treatments.
Community engagement is a key pillar of IMMUNEQUITY, with the team working closely with communities affected by HIV to shape every aspect of the project, from planning real-world implementation to designing future clinical trials.
The partnership with Ugandan organizations, such as the Joint Clinical Research Centre (JCRC) and Makerere University, brings a wealth of expertise and local knowledge to the table. This collaboration, formalized in 2022, allows for the co-development and testing of technologies in Uganda.
The economic implications of this initiative are significant. With the majority of individuals living with HIV residing in low- to middle-income countries, ensuring accessibility is crucial. In countries like Uganda, HIV treatments using generic ART can cost approximately US$1,000 per person annually, representing a lifelong expense and a heavy burden on health systems. In contrast, in high-income countries like Canada and the United States, branded drug pricing and clinical care raise the annual cost of ART to approximately US$30,000 or more per person.
A safe and effective one-time cure would provide economic benefits globally, and building capacity in biotherapeutics strengthens Canada's biomedical sector, creates high-quality jobs, and positions Canadian institutions as leaders in equitable innovation.
"Scientific success is just the beginning," Arts emphasizes. "The best cure is one that can be produced on a large scale and at an affordable cost in resource-limited settings. Otherwise, it remains out of reach and people will not trust it."
The vision of IMMUNEQUITY goes beyond curing HIV. The team aims to pioneer a new model of biomedical innovation, bridging the gap between discovery and access. If successful, this framework of co-development, frugal engineering, local manufacturing, and community partnership could be applied to other infectious diseases and chronic conditions in low- and middle-income countries.
In the global fight against HIV, science has made remarkable progress. The researchers behind IMMUNEQUITY want to ensure that the next breakthrough, an accessible HIV cure, is not just for the privileged few but for everyone, bringing an end to the HIV epidemic.
"IMMUNEQUITY represents a paradigm shift in scientific thinking. Equitable access is not an afterthought; it is a driving principle from the very start," Arts concludes.
Let's continue the conversation in the comments. Do you think initiatives like IMMUNEQUITY can truly revolutionize access to healthcare? What are your thoughts on the potential impact of this initiative?
